Douglas Grier, MD
Urology · Bristol, TNNPI 1922035922
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $19,025 of the $30,825 with a category attached, or 61.7%. 23 manufacturers reported payments, led by Neotract Inc. at 43.2% of the total. Reporting peaked in 2019 at $27,379 and has fallen 99.6% since, to $111 in 2025. Among urology clinicians in TN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $489.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$13K
- Astellas Pharma US Inc$11K
- Uromedica, Incorporated$3K
- Verathon Inc.$1K
- Fujifilm Sonosite, Inc.$800
- Teleflex LLC$400
- plus $1K from 17 others
Across 1 payment — averaging $1696.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neotract Inc.$2K
What the payments were for
- Consulting fees$3,42511%
- Speaking & faculty fees$19,02562%
- Travel & lodging$6,34921%
- Food & beverage$2,0187%
- Education$80%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 15 | $13,319 |
| Astellas Pharma US Inc | 10 | $10,921 |
| Uromedica, Incorporated | 4 | $3,161 |
| Verathon Inc. | 2 | $1,200 |
| Fujifilm Sonosite, Inc. | 1 | $800 |
| Teleflex LLC | 1 | $400 |
| Lilly USA, LLC | 1 | $225 |
| Johnson & Johnson | 4 | $173 |
| Myovant Sciences Inc. | 2 | $128 |
| Boston Scientific | 1 | $116 |
| Endo USA, Inc. | 3 | $53 |
| Verity Pharmaceuticals Inc. | 2 | $50 |
| Procept Biorobotics Corporation | 1 | $45 |
| Urogen Pharma, Inc. | 2 | $44 |
| Myriad Genetic Laboratories, Inc. | 2 | $39 |
| Axonics, Inc. | 2 | $31 |
| Immunitybio, Inc. | 1 | $26 |
| Koelis Inc. | 1 | $20 |
| Tolmar, Inc. | 1 | $18 |
| Vertex | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Travere Therapeutics, Inc. | 4 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$13,164
- MYRBETRIQ$10,883
- ProACT$3,118
- NPD Clinical Study$1,200
- SONOSITE PX ULTRASOUND SYSTEM$800
- UroLift System$400
- ORGOVYX$118
- GENERAL MALE SUI$116
- Erleada$106
How this compares
$30,825 in reported general payments places this provider in the 90th percentile of 276 urology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 16 | $9,934 |
| MyrbetriqMirabegron | 11 | $5,339 |
| Solifenacin Succinate | 23 | $2,953 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $394 |
| Tamsulosin Hcl | 24 | $235 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $9,93416 claims |
| Astellas Pharma US IncMyrbetriq | $10,921 | $5,33911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 276 urology providers in Tennessee.
Other urology in Bristol
- John CourseyBristol$15K
- L KnollNashville$2.1M
- David GubinMemphis$1M
- Gautam JayramNashville$1M
- David MorrisHendersonville$871K
- Roger DmochowskiNashville$763K
- Paul EberGermantown$476K
- Ashley TapscottNashville$425K
- Raoul ConcepcionNashville$339K
- Melissa KaufmanNashville$312K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.